Supplementary Table S2 from Efficacy of the Allosteric MEK Inhibitor Trametinib in Relapsed and Refractory Juvenile Myelomonocytic Leukemia: a Report from the Children’s Oncology Group
Year: 2026
Type: supplementary-materials
Abstract: Qualitative and Quantitative Summary of Abnormal Peripheral Blood and Bone Marrow Findings.
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: gold
OpenAlex ID: W7165010249
Cites:
Cited by:
Related to: